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Investigation in the ﬁeld of Alzheimer’s disease (AD), the commonest cause of dementia,
has been very active in recent years and it may be difﬁcult for the clinician to keep up with
all the innovations and to be aware of the implications they have in clinical practice. The
authors, thus, reviewed recent literature on the theme in order to provide the clinician with
an updated overview, intended to support decision-making on aspects of diagnosis and
management. This article begins to focus on the concept of AD and on its pathogenesis.
Afterward, epidemiology and non-genetic risk factors are approached. Genetics, including
genetic risk factors and guidelines for genetic testing, are mentioned next. Recommenda-
tions for diagnosis of AD, including recently proposed criteria, are then reviewed. Data on
the variants of AD is presented. First approach to the patient is dealt with next, followed
by neuropsychological evaluation. Biomarkers, namely magnetic resonance imaging, sin-
gle photon emission tomography, FDG PET, PiB PET, CSF tau, and Aβ analysis, as well as
available data on their diagnostic accuracy, are also discussed. Factors predicting rate of dis-
ease progression are brieﬂy mentioned. Finally, non-pharmacological and pharmacological
treatments, including established and emerging drugs, are addressed.
Keywords:Alzheimer,AD pathogenesis,AD genetics,AD diagnosis,AD variants,AD neuropsychological evaluation,
AD biomarkers, AD treatment
CONCEPT OF ALZHEIMER’S DISEASE
Thepresent conceptualizationof Alzheimer’s disease (AD) is based
on autopsy ﬁndings of widespread neuritic plaques and neuroﬁb-
rillary tangles (NFT), described for the ﬁrst time in 1906 by Alois
Alzheimer in a case with early symptom onset (Alzheimer et al.,
1995). The concept was subsequently generalized to late-onset
cases when Blessed et al. observed identical pathology in elderly
patients (Blessed et al., 1968; Seshadri et al., 2011).
The term “AD” may have distinct meanings in different con-
texts. AD has, in some settings, referred to the neuropathological
criteria for AD, and, in other, to the clinical syndrome of progres-
sive cognitive decline, typically at the stage of AD dementia (Sper-
ling et al., 2011). The National Institute on Aging-Alzheimer’s
Association (NIA-AA)workgroup on diagnostic guidelines forAD
decided to deﬁneAD as encompassing the underlying pathophysi-
ological disease process (Sperling et al., 2011) as opposed to having
AD connote only the clinical stages of disease as proposed by the
International Working Group for New Research Criteria for the
Diagnosis of AD (Dubois et al., 2010). The NIA-AA workgroup
thus considers that AD can be used to refer to dementia stages, as
well as to MCI and pre-MCI phases.
Evidence from genetic at-risk and aging cohorts suggests that
there may be a time lag of at least a decade between the begin-
ning of the pathological cascade of AD and the onset of clinical
impairment. The NIA-AA workgroup postulates that individu-
als with biomarker evidence of early AD pathology (AD-P) are
at increased risk of progression to AD dementia (AD-D). How-
ever, the ability of the biomarkers of AD-P to predict the ulterior
clinical course of cognitively normal persons remains to be estab-
lished, and it is acknowledged that some of these individuals will
never exhibit clinical symptoms in their lifetime (Sperling et al.,
2011).
PATHOGENESIS
AD is the most frequent cerebral proteopathy (Jucker and Walker,
2011). Macroscopically, the AD brain is characterized by atro-
phy of the hippocampal formation and of the cerebral cortex,
primarily involving the fronto-temporal association cortex, com-
bined with ventricular enlargement, especially of the temporal
horn, all of these ﬁndings being greater than expected for age
(Walsh and Selkoe, 2004; Perl, 2010). Microscopically, its neu-
ropathological hallmarks are the combined presence of extracel-
lular β–amyloid-containing plaques and intraneuronal NFTs, the
latter being formed by abnormally hyperphosphorylated tau pro-
tein (Terry, 1963; Alzheimer et al., 1995). The β-amyloid (Aβ)
peptide and tau protein are thought to play a critical role in AD
development, but several other mechanisms of neurodegenera-
tion have been proposed, including pro-inﬂammatory responses
(Wyss-Coray, 2007), mitochondrial dysfunction (Reddy, 2011),
oxidative stress (Cai et al., 2011),genetic and environmental factors
(Nelson et al., 2011), and apoptosis (Cai et al., 2011). The deleteri-
ous effects of these pathological changes provide the substrate for
the etiopathogenesis of AD, and converge, ultimately, to synaptic
dysfunction and neuronal cell loss (Götz et al., 2004; Walsh and
Selkoe, 2004; LaFerla and Oddo, 2005; Arendt, 2009; Takahashi
et al., 2010). This process occurs in particularly vulnerable brain
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areas, such as those responsible formemory and cognition,namely
the limbic and association cortices and some subcortical nuclei
with large cortical projections (Walsh and Selkoe, 2004; LaFerla,
2010; Perl, 2010).
The pathological interaction between Aβ42 and tau proteins
and their relative contribution to neurodegeneration, synaptic and
neuronal loss have been extensively investigated, but still remain
to be completely elucidated.
The β-amyloid protein, a physiological peptide with a char-
acteristic β-pleated sheet conﬁguration, derives from sequential
cleavage of the amyloid precursor protein (APP) by β secretase,
followed by γ secretase (Glenner and Wong, 1984). Aβ can vary in
length at the c-terminus, according to the pattern of cleavage of
APP. The Aβ1–40 isoform (with a total of 40 amino acid residues)
is the most prevalent, followed by the Aβ1–42 isoform (with 42
amino acid residues). The latter has hydrophobic properties and
aggregates more readily than the Aβ1–40 isoform, which turns it
more amyloidogenic and prone to polymerize (Perl, 2010). Aβ
that escapes fromproteolytic degradation aggregates andpolymer-
izes in various structurally distinct forms, including oligomeric,
protoﬁbrillar, amylospheroid, and ﬁbrillar forms.
In the AD brain, neuritic plaques are composed of a central
core containing β-amyloid protein, surrounded by clusters of dys-
trophic axons and dendrites (or neurites) and by glial recruitment
(LaFerla and Oddo, 2005; Perl, 2010). Aβ deposits also tend to
accumulate in the walls of the leptomeningeal, cerebral cortical
and cerebellar blood vessels. Cerebral amyloid angiopathy is cor-
relatedwithADpathogenesis andmay lead to vascular rupture and
multiple lobar hemorrhages (Nicoll et al., 2004). The Aβ deposi-
tion on parenchyma or vascular walls in the brain appears to result
froman increased anabolic activity or a decreased catabolic activity
of Aβ.
Several mutations involving the APP gene, or genes encod-
ing secretase complex components, can promote the amyloido-
genic pathway and increase the Aβ42/Aβ40 ratio, promoting its
aggregation. The study of the early onset familiar forms of AD,
histopathologically indistinguishable from the sporadic form,pro-
vides compelling evidence for the Aβ protein role in the initiation
of the neurotoxic cascade, corroborated by experiments involving
animal and tissue-culture models (Götz et al., 2004). However, for
the AD sporadic form, which is the more prevalent, totaling more
than 95% of cases, the pathogenic trigger remains unidentiﬁed
(Götz et al., 2004).
The “amyloid cascade hypothesis” postulates that the excessive
formation and deposition of insoluble ﬁbrillar Aβ, with conse-
quent aggregation in plaques, is the initiating event in AD patho-
genesis. This ﬁrst insult triggers, secondarily, a neurotoxic cascade,
including NFT formation, which ultimately leads to synaptic and
neuronal loss in critical areas related with cognitive functions like
memory (Herrup, 2010). However, neuropathological investiga-
tions have found a weak correlation between cerebral amyloid
plaque burden and the severity of dementia (Terry et al., 1991;
Nagy et al., 1996; Ingelsson, 2004).Moreover, evidence fromearlier
studies has suggested that the formation of soluble non-ﬁbrillar
Aβ42 assemblies, termed oligomers and composed of small aggre-
gates of 2–12 Aβ peptides, rather than insoluble amyloid plaques,
may play a pivotal role in theADneurodegenerative cascade. Some
in vitro studies suggest that, in the early stages of AD,Aβ oligomers,
through a potent pro-inﬂammatory response induction, attenu-
ate microglial phagocytic function and, consequently, impair the
clearance of ﬁbrillar Aβ, promoting its deposition in the brain
(Pan, 2011). In animal models, Aβ oligomers can be found in the
hipoccampal CA1 region and in the entorhinal cortex, prior to the
development of amyloid plaques and NFT (Wirths et al., 2001).
There is also robust evidence, from studies involving transgenic
mice and/or human AD patients, demonstrating that the early
accumulation of intraneuronal Aβ oligomers can induce down-
stream effects, such as mitochondrial dysfunction (LaFerla et al.,
2007; Amadoro et al., 2012), microgliosis and astrocytosis (Walsh
and Selkoe, 2004), free radicals formation, oxidative stress and
hyperphosphorylation of tau protein (Walsh and Selkoe, 2004;
LaFerla and Oddo, 2005), synaptic dysfunction and neurotrans-
mitter deﬁcits (Walsh and Selkoe, 2004; Bao et al., 2012), leading
to synaptic dysruption and cognitive decline (Walsh and Selkoe,
2004; LaFerla and Oddo, 2005; Arendt, 2009).
Besides amyloid plaques, the other major histopathological
hallmark of AD consists of intraneuronal neuroﬁbrillary lesions,
which appear as NFT in soma or apical dendrites, as neuropil
threads in distal dendrites and associated with Aβ plaques in
dystrophic neurites. These proteinaceous aggregates consist of
paired helical ﬁlaments, formed by hyperphosphorylated tau pro-
tein. Tau is a microtubule-associated protein, responsible for the
assembly and stability of microtubules in the neuronal cell and
for axoplasmatic transport. The microtubule connection is reg-
ulated by a complex interplay of isoform tau expression and
tau phosphorylation (Perl, 2010). In the AD brain, tau pro-
tein becomes abnormally hyperphosphorylated at several Ser/Thr
residues, detaches from axonal microtubules and aggregates into
insoluble NFT. These changes result in disruption of axonal trans-
port and intracellular organelles, including mitochondria (Reddy,
2011). Several phosphokinases have been implicated in tau hyper-
phosphorylation, namely glycogen synthase kinase 3β (GSK3β),
cyclin dependent kinase 5 (CDK5) and extracellular signal-related
kinase 2 (ERK2; Ballard et al., 2011a). Tau protein is the main
constituent of NFT, but other proteins have been identiﬁed, such
as ubiquitin (Perry et al., 1987), cholinesterases (Mesulam and
Moran, 1987) and A4 amyloid protein (Hyman et al., 1989).
There is evidence, based on an animal and tissue-culture study,
that neuroﬁbrillar degeneration may trigger or facilitate multi-
ple pathological changes, including intraneuronal Aβ deposition,
oxidative damage and glial activation, all of which can participate
in mitochondrial dysfunction and neuronal damage (Götz et al.,
2004).
Contrarily to what was observed for amyloid plaques, severity
of dementia has been strongly correlated with NFT density (in
studies involving human AD patients; Nagy et al., 1996), as well as
with soluble oligomeric Aβ (Arendt, 2009).
Tau deposition and neurodegeneration occur in stereotyped
fashion, progressing over six stages: stages I–II represent the clin-
ically silent involvement of transentorhinal cortex; stages III–IV
are characterized by lesions in entorhinal/transentorhinal regions
and correspond to the phase of mild cognitive decline; in stages
V–VI, there is severe neocortical destruction and fully developed
dementia (Braak andBraak, 1995; Perl, 2010). Recent investigation
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involving human brains indicates that pre-tangle material, able to
induce NFT pathology, develops early in noradrenergic projection
neurons of the locus coeruleus, before involvement of the transen-
torhinal region (Braak and Del Tredici, 2011). Tau pathology may
then progress in a prodromical phase, during ﬁve or more decades,
until it reaches a clinical threshold (Hyman and Goméz-Isla, 1994;
Braak and Del Tredici, 2011; Nelson et al., 2011). These ﬁndings
indicate that AD is not a mere extension of normal aging and chal-
lenge the traditional view suggesting that Aβ deposition precedes
and triggers tau pathology (Gómez-Ramos and Asunción Morán,
2007; Braak and Del Tredici, 2011).
Synaptic loss in the hippocampus and neocortex is widely con-
sidered the major correlate of cognitive decline (Terry et al., 1991;
Coleman andYao,2003;Walsh and Selkoe,2004).Defects in synap-
tic transmission occur early in the disease, before the deposition of
amyloid plaques or NFTs, and progress slowly (Walsh and Selkoe,
2004;Arendt, 2009). Several studies usingADhuman samples have
found reduced expression of a group of genes encoding proteins
involved in synaptic vesicle trafﬁc, with consequent depletion of
neurotransmitter systems and synaptic/neuronal loss (Coleman
and Yao, 2003; Yao et al., 2003). Synaptic failure may lead to dis-
ruption of neuronal circuits and subsequently result in cognitive
decline, even before structural cellular lesions (Yao et al., 2003;
Arendt, 2009).
Studies on AD human samples indicate a strong anatomical
correlation between synaptic loss markers and tangle forma-
tion (Honer et al., 1992; Callahan et al., 1999, 2002; Coleman
and Yao, 2003). Furthermore, investigation using animal models
has demonstrated the combined occurrence of Aβ42 and hyper-
phosphorylated tau in hippocampal CA1 region, within neurites
and postsynaptically, during the early stages of AD pathogenesis
(Takahashi et al., 2010).
Despite major advances in our understanding of the AD neu-
ropathology, it is still a matter of great debate and much remains
to be explained.
GENETICS
GENETIC RISK FACTORS
AD can be divided into early (<60–65 years) and late (>60–
65 years) onset forms.According to family history,ADcasesmaybe
classiﬁed as autosomal dominant, familial or sporadic (Goldman
et al., 2011; Table 1).
Late-onset AD has a substantial genetic component, with an
estimated heritability of 58–79% (Gatz et al., 2006; Wingo et al.,
2012). It is probably governed by an array of low penetrance com-
mon risk alleles across a number of different loci (Avramopoulos,
2009). In the early 1990s, the association between the APOE gene
and late-onset AD was described (Corder et al., 1993; Saunders
et al., 1993; Strittmatter et al., 1993a,b). The APOE gene has been
repeatedly implicated in the pathogenesis of AD and a Genome-
Wide Association Study (GWAS) conﬁrmed that this is the major
susceptibility gene for late-onset forms (Coon et al., 2007). There
are three common alleles of APOE (ε2, ε3, ε4), corresponding to
six phenotypes. AD is associated with the ε4 allele, the presence
of which increases the risk and reduces the average age at onset of
AD in a dose-dependent manner (carriers of two APOE ε4 alleles
have a higher risk and an earlier onset of AD than heterozygous
subjects). Estimates of the increased risk conferred by theAPOE ε4
vary widely. In a recent study, the lifetime risk of AD at the age of
85 ranged from51 to 52% forAPOE ε4/ε4male carriers to 60–68%
forAPOE ε4/ε4 female carriers and from22 to 23% forAPOE ε4/ε3
male carriers to 30–35% for APOE ε4/ε3 female carriers. The odds
ratio for AD of onset between the ages of 60 and 69 was of 35.1 in
APOE ε4 homozygotes and of 4.2 in ε4/ε3 heterozygotes (Genin
et al., 2011). APOE ε4 allele is neither necessary nor sufﬁcient for
developing AD (Corder et al., 1993; Farrer et al., 1997).
The early onset forms comprise about 6–7% of all cases of
AD (Campion et al., 1999; Nussbaum and Ellis, 2003). Autoso-
mal dominant disease is usually found in early onset AD families
(Bertram and Tanzi, 2005). However, almost 40% of the patients
with early onset AD are sporadic cases (with a negative family
history; van Duijn et al., 1994; Campion et al., 1999). Three genes
have been implicated in early onsetAD:APP,presenilin 1 (PSEN1),
and presenilin 2 (PSEN2). The discovery of the ﬁrst autosomal
dominant mutations in APP (Goate et al., 1991) was followed
by the identiﬁcation of autosomal dominant mutations in the
PSEN1 (Schellenberg et al., 1992; Sherrington et al., 1995) and
PSEN2 genes (Levy-Lahad et al., 1995a,b; Rogaev et al., 1995).
The mutations in any of these three genes result in a shift in the
metabolism of APP such that more of a 42 aminoacid form of
Aβ is produced (Hardy, 1997). These mutations cause AD with
nearly complete penetrance. Nevertheless, they may present with
heterogeneous phenotypes (Sherrington et al., 1996; Tedde et al.,
2003), and recently an APP mutation that causes disease only in
Table 1 | Alzheimer Disease Genetics Division according to the American College of Medical Genetics and the National Society of Genetic
Counselors.
Feature Definition
Age of onset Early onset (∼6–7%)* <60–65 years
Late-onset (∼93–94%)* >60–65 years
Family history Autosomal dominant (<5%) Disease that occurs in at least three individuals in two ormore generations, with two of the individuals
being ﬁrst-degree relatives of the third
Familial (∼15–25%) Disease that occurs in more than one individual and at least two of the affected individuals are
third-degree relatives or closer
Sporadic (∼75%) Isolated case in the family or cases separated by more than three degrees of relationship
*Campion et al. (1999), Nussbaum and Ellis (2003).
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the homozygous state was described (Di Fede et al., 2009). In
contrast to mutations in PSEN1, mutations in PSEN2 are a rela-
tively rare cause of familial AD (Sherrington et al., 1996; Campion
et al., 1999). The age of symptom onset in patients with PSEN1
mutations is generally 25–65 years and it is similar among affected
members of the same family. In contrast, individuals with PSEN2
are typically older at presentation (45–88 years) and the age of
onset is variable among relatives of the same family (Sherrington
et al., 1996). Mutations in APP, PSEN1, and PSEN2 are found in
up to 82% of patients with autosomal dominant AD. It is likely
that additional genes inﬂuence the pathophysiology of early onset
AD (Janssen et al., 2003; Goldman et al., 2011). APOE gene is a
risk factor for early onset AD (van Duijn et al., 1994) with odds
ratio of 5.6 in ε4 homozygous individuals and of 2.1 in heterozy-
gous ε4/ε3 cases (Genin et al., 2011). A recent study estimates that
the early onset AD heritability is of 92–100%, which is compati-
ble with an almost entirely genetically based disease. However, the
concordance among siblings is of 21.6% and between parents and
offspring of 10% or less. The authors (Wingo et al., 2012) consider
that the most likely explanation for these results is that approxi-
mately 90% of early onset AD cases are due to autosomal recessive
causes.
Since 2009, four GWAS and a three-stage analysis of the GWAS
resulted in the identiﬁcation of nine novel loci associated with
late-onset AD: CLU, PICALM, CR1, BIN1, ABCA7, MS4A cluster
(MS4A6A/MS4A4E), CD2AP, CD33, and EPHA1 (Harold et al.,
2009; Lambert et al., 2009; Seshadri et al., 2010; Hollingworth
et al., 2011a,b; Naj et al., 2011). Other studies replicated some
of these associations (Carrasquillo et al., 2010, 2011a,b; Corne-
veaux et al., 2010; Jun et al., 2010; Antúnez et al., 2011a,b; Lambert
et al., 2011; Kamboh et al., 2012). Examining the amount of
genetic risk effect attributable to these genes (other than APOE),
the most strongly associated single-nucleotide polymorphisms at
each locus have population attributable fractions between 2.72
and 5.97%, with a cumulative population attributable fraction
for non-APOE loci estimated to be as much as 35% (Naj et al.,
2011).
It has been suggested (Lambert et al., 2009; Lambert and
Amouyel, 2011) that, in familial early onset AD, the Aβ peptides
accumulate through overproduction and that, in late-onset forms,
the Aβ excessive deposition is related to an insidious impairment
of clearance of Aβ peptides (Mawuenyega et al., 2010).
Morgan (2011) described three new pathways implicated in
late-onset AD:
(1) Immune system function (implicated genes: CLU, CR1,
ABCA7, MS4A cluster, CD33 and EPHA1). Speciﬁc immune
responses may be capable of inducing Aβ degradation, avoid-
ing accumulation of these peptides (Lambert and Amouyel,
2011). It was also suggested that AD risk variants may
cause changes to the complement system, which can re-ignite
programmed synaptic loss (Hollingworth et al., 2011b).
(2) Cholesterol metabolism (implicated genes: APOE, CLU, and
ABCA7 ).As cholesterol promotes synapse formation, interfer-
ence with cholesterol processing throughAD risk gene activity
can be a mechanism of synaptic disintegration (Hollingworth
et al., 2011b).
(3) Synaptic dysfunction and cell membrane processes (impli-
cated genes: PICALM, BIN1, CD33, CD2AP, and EPHA1),
including endocytosis (Hollingworth et al., 2011a). Although
these processes diverge from the amyloid hypothesis, it was
suggested that toxic Aβmay have a modulatory effect on them
(Morgan, 2011).
SORL1 is involved in the processing and trafﬁcking of APP into
recycling pathways, as demonstrated in a study involving in vitro
experiments, mice models and human AD samples (Andersen
et al., 2005). A recent meta-analysis of genetic data from case-
control studies suggests that mutations in SORL1 may play a role
in the pathogenesis of late-onset AD (Reitz et al., 2011), but their
effect on the risk of disease seems to be modest (Rogaeva et al.,
2007).
Recently, a variable-length poly-T (deoxythymidine homopoly-
mer) polymorphism in the TOMM40 gene, which is located next
to the APOE gene in a region of strong linkage disequilibrium,
was described and found to be associated with the age of onset of
late-onset AD (Lutz et al., 2010; Roses, 2010; Roses et al., 2010).
This association is still uncertain and it is unknown whether the
poly-T repeat affects risk of AD through an APOE-dependent or
a totally independent mechanism (Cruchaga et al., 2011).
GENETIC TESTING
The American College of Medical Genetics and the National Soci-
ety of Genetic Counselors have recently deﬁned guidelines con-
cerning genetic counseling and testing for AD (Goldman et al.,
2011). Tests for genes associated with early onset AD (currently
APP, PSEN1, and PSEN2) are useful for: (1) symptomatic patients
with early onset AD; (2) individuals with a family history of
dementia with one or more cases of early onset AD; (3) individuals
with a relative affected by a known mutation of APP, PSEN1, or
PSEN2.
In summary, AD genetic risk factors may be divided into: (1)
rare autosomal dominant mutations (APP, PSEN1, PSEN2) –
genetic tests available in selected circumstances; (2) common
mutations with moderate effect (APOE) – genetic testing not
recommended at present due to limited clinical utility and poor
predictive value; (3) common mutations with small effect (e.g.,
CLU, PICALM, CR1, BIN1, ABCA7, MS4A6A, MS4A4E, CD2AP,
CD33, andEPHA1) – geneswithpoorpredictive value individually.
Genetic counseling is essential during the process of genetic
testing for both symptomatic and asymptomatic patients. Pedi-
atric testing is not recommended (Goldman et al., 2011).
NON-GENETIC RISK FACTORS
AD is a multifactorial disorder, whose causes remain largely
unknown. Despite extensive research on genetic factors, the vast
majority of AD cases are not directly linked to them. Instead,
a complex association between environmental or lifestyle and
polygenetic factors seems to play a crucial role in sporadic AD
vulnerability (Launer, 2002; Murray et al., 2011).
Aging is, by far, the most well established risk factor for the
development of sporadic AD. Several studies are unanimous in
showing an exponential growth in incidence rates between the
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ages of 65 and 85 years, doubling every 5 years, and no gender dif-
ferences in the AD incidence (Launer et al., 1999; Fratiglioni et al.,
2000; Kawas and Corrada, 2006). In contrast, after the age of 85,
the cumulative risk for developing AD seems to decrease only in
men. Thus, the female gender is often associated with a higher
relative risk of AD (Andersen et al., 1999; Ruitenberg et al., 2001).
Modiﬁable risk factors have received increasing attention. Epi-
demiological and clinical studies suggest that vascular and meta-
bolic disorders are important risk factors for AD. Growing evi-
dence has emerged suggesting that raised blood pressure (Qiu
et al., 2006) and high levels of serum cholesterol (Kivipelto et al.,
2005), particularly at adult age, may precede and increase the
risk of dementia, including AD, in late life. The biological path-
way linking long-standing hypertension or hypercholesterolemia
to AD pathology can be mediated by atherosclerotic lesions and
other vascular changes. These lead to chronic or episodic cerebral
hypoperfusion and may converge to initiate or accelerate selec-
tive neurodegenerative processes in the aging brain, particularly
in genetically susceptible hosts (Iadecola and Gorelick, 2003; de la
Torre, 2004; Qiu et al., 2006). The hypercholesterolemia’s effects
in AD incidence may also be due to an increased synthesis of Aβ42,
through modulation of the cleavage pattern of APP, or to inter-
ference with the transport and metabolism of this peptide (Kuller
and Lopez, 2011). Cardiovascular disease and carotid artery steno-
sis are strong risk factors, supporting the view that chronic cerebral
hypoperfusion may promote selective neurodegenerative damages
in susceptible brain areas (Ruitenberg et al., 2005) and suggesting
that peripheral atherosclerosis biomarkers can be early indicators
of a subclinical phase of AD (Qiu et al., 2006; Muller et al., 2007).
Cerebrovascular disease is an important pathological mechanism
adding severity to AD (Knopman, 2006). Similarly to hyper-
tension, overweight and obesity initiated at adulthood seem to
increase the susceptibility for AD (Kivipelto et al., 2005), possibly
through vascular dysfunction or through the effects of hormonal
compounds that are secreted by the adipose tissue (Gustafson,
2006). Diabetes and impaired glucose tolerance have also been
associated with increased odds of dementia (Biessels et al., 2006;
Qiu et al., 2007). The direct effect of glucose-mediated toxicity and
hyperinsulinemia on amyloid metabolism and AD neurodegener-
ative processes has been emphasized (Biessels et al., 2006), but the
exact pathophysiological mechanisms remain unclear.
The vascular hypothesis suggests that midlife vascular risk fac-
tors and disorders are involved in neurodegeneration, progression
and clinical presentation of AD. The view that sporadic AD is pri-
marily a vascular diseasewithneurodegenerative consequences (de
la Torre, 2010) remains controversial, given that both cerebrovas-
cular disease andADare very prevalent in the elderly, and thusmay
coexist in an important proportion of patients. Furthermore, the
identiﬁcation of “pure forms” of AD, i.e., without simultaneous
vascular disease, does not support a direct relationship between
vascular disease and AD (Román and Royall, 2004).
Concerning tobacco smoking, conﬂicting outcomes have been
reported. Contradicting previous reports, recent studies have
found that current smoking is associated with increased risk of
AD in older people (Cataldo et al., 2010). With regard to alco-
hol intake, the outcomes are also controversial, but suggest that
light to moderate consumption may decrease the risk of dementia,
when compared to abstinence or heavy drinking, in a J-shaped
relationship (Xu et al., 2009).
Additional risk factors have been suggested, including migraine
(Tyas et al., 2001), high intake of saturated fat (Luchsinger and
Mayeux, 2004), high serum homocysteine (Kalmijn et al., 1999)
and ﬁbrinogen concentrations (Bots et al., 1998), peripheral
inﬂammation (Engelhart et al., 2004), atrial ﬁbrillation (Duron
and Hanon, 2010) and head injury (Guo et al., 2000).
In the elderly population, studies show a strong inverse asso-
ciation between the levels of mental, social and physical activity
and the dementia risk (Wang et al., 2002; Rovio et al., 2005). The
potential pathway explaining the effects of lifestyle factors on AD
risk can be explained by the cognitive reserve hypothesis, which
states that educational or occupational stimulation may lead to a
more effective and ﬂexible use of brain networks, resulting in an
increase of cognitive functional reserve against brain pathology or
age-related changes. Thus, stimulating environments and physical
exercise can be protective factors and may modulate the thresh-
old of clinical expression of AD pathology (Fratiglioni et al., 2004;
Stern, 2006).
EPIDEMIOLOGY
AD is themost common cause of dementia (Fratiglioni et al., 2000;
Lobo et al., 2000). By 2005, the Delphi study estimated that there
were 24.3 million people worldwide with dementia, with 4.6 mil-
lion new cases arising every year. Among regional populations of
individuals aged ≥60 years, those from North America and West-
ern Europe exhibited the highest prevalence of dementia (6.4 and
5.4%, respectively), followed by those from Latin America (4.9%),
China and developing Western Paciﬁc (4.0%) and Eastern Europe
(3.8–3.9%). The annual regional dementia incidence rates (per
1.000 individuals) were estimated to be 10.5 for North America,
9.2 for Latin America, 8.8 for Western Europe, 8.0 for China and
developing Western Paciﬁc and 7.7–8.1 for Eastern Europe. It has
been calculated that the number of people with dementia may rise
to 81.1 million by 2040 (Ferri et al., 2005).
The estimated lifetime risk of AD is 10–11% in males and 14–
17% in females at the age of 85 (Genin et al., 2011). Women bear
most of the burden of AD probably due to longer life expectancy
and longer post-diagnosis survival duration. However, reports of
the association between gender and AD have been controversial
and its unclear whether women have a survival advantage or not
(Heyman et al., 1996; Lapane et al., 2001; Brookmeyer et al., 2002;
Larson et al., 2004; Helzner et al., 2008; Xie et al., 2008). In some
studies, age-speciﬁc incidence of AD and prevalence controlled
for age do not differ signiﬁcantly by gender (Hebert et al., 2001).
Interestingly, a study reported that AD pathology is more likely to
be clinically expressed as dementia in women than in men (Barnes
et al., 2005).
The prevalence and incidence rates for AD increase exponen-
tially with age. AD rates rise from 2.8 per 1000 person-years in the
age group 65–69 years to 56.1 per 1000 person-years in the older
than 90-year age group (Kukull et al., 2002).
AD substantially reduces life expectancy and increases the prob-
ability of being admitted to a nursing home. The median survival
times after diagnosis range from 8.3 years for individuals diag-
nosed with AD at the age of 65–3.4 years for persons diagnosed
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as having AD at the age of 90. Diagnoses of AD at ages 65 and
90 years are associatedwith approximately a 67 and 39% reduction
in median life span, respectively (Brookmeyer et al., 2002). Death
from all causes by the age of 80 is expected in 61% of AD patients
and in 30% of the general population. Nursing home admission
by the age of 80 years is expected for ∼75% of the surviving AD
patients, and only for 4% of the general population (Arrighi et al.,
2010).
DIAGNOSIS
The clinical diagnosis of dementia caused by AD can approach an
accuracy rate of 95%, but only when it is established by highly
experienced clinicians observing selected patients who are gener-
ally followed up comprehensively over time. Outside of specialized
centers, AD dementia is correctly diagnosed only in about 50% of
affected individuals (Mayeux et al., 2011). Accurate diagnosis of
AD is difﬁcult because of the frequent presence, in older adults,
of co-morbidities that can contribute to cognitive impairment.
A factor that may further complicate diagnosis is ignorance of
the patient’s previous baseline, which precludes the clinician from
correctly evaluating whether there was cognitive and functional
decline (a requisite incorporating MCI and dementia criteria) or
not. Theremaynot always be a reliable informant and self-reported
estimates of function can be inaccurate (Mayeux et al., 2011).
The diagnosis of AD is frequently based on the criteria of the
Diagnostic and Statistical Manual of Mental Disorders, fourth edi-
tion (DSM-IV-TR; American Psychiatric Association, 2000) and
on the National Institute of Neurologic and Communicative Dis-
orders andStroke –AlzheimerDisease andRelatedDisordersAsso-
ciation (NINCDS-ADRDA) criteria (McKhann et al., 1984). Both
sets of criteria require deﬁcits in memory and at least one other
cognitive domain. The DSM-IV-TR criteria additionally stipulate
that there must be an impact of the cognitive impairment on
social function or activities of daily living (ADL). According to the
NINCDS-ADRDAcriteria, theADdiagnosis is classiﬁed as deﬁnite
(clinical diagnosis with histologic conﬁrmation), probable (typi-
cal clinical syndromewithout histologic conﬁrmation),or possible
(atypical clinical features but no alternative diagnosis apparent;
no histologic conﬁrmation). The NINCDS-ADRDA criteria have
been reasonably reliable for the diagnosis of probable AD: across
more than a dozen clinical-pathological studies, they have had a
sensitivity of 81% and a speciﬁcity of 70% (Knopman et al., 2001).
However, using the DSM-IV-TR and the 1984 NINCDS-
ADRDA recommendations, the AD cases are discovered late in
the disease process. Therefore, substantial efforts have been made
to create criteria for the clinical stage preceding dementia, i.e.,mild
cognitive impairment (MCI; Petersen and Negash, 2008), a state
in which, by deﬁnition, ADL are essentially normal. Nevertheless,
MCI is a heterogenous entity, encompassing not onlyAD cases, but
also patientswithdegenerative diseases other thanADand individ-
uals with non-degenerative causes of cognitive impairment. This
issue was solved with the creation of the concept of prodromal
AD, which may be considered a subtype of MCI, by Dubois et al.
(2007). The core principle of the research criteria for the diagnosis
of AD proposed by this group (Dubois et al., 2007) is based upon
the presence of consistent episodic memory disturbance which,
together with biomarker positivity, recognizes AD across the full
spectrum of the clinical disease. To fulﬁll criteria for probable AD,
a patientmustmeet the cornerstone clinical criterionA and at least
one of the supportive biomarker criteria. CriterionA speciﬁes that
there must be an episodic memory deﬁcit within test conditions of
encoding speciﬁcity. The presence of a biological footprint of the
disease is established either by criterion B (structural imaging),
criterion C (cerebrospinal ﬂuid), criterion D (molecular imag-
ing), or criterion E (dominant mutation within the immediate
family). Apart from the incorporation of biomarkers, two relevant
innovations characterize the Dubois criteria: (1) the presence of
a progressive memory deﬁcit is considered sufﬁcient to make a
diagnosis of AD, even if it is the patient’s only cognitive deﬁcit; (2)
the declarative memory impairment necessary for diagnosis is of
the “medial temporal lobe type” (Carlesimo et al., 2011).
In 2011, the NIA-AA workgroup published recommendations
concerning the deﬁnition of the preclinical stages of AD (Sper-
ling et al., 2011), the diagnosis of MCI due to AD (MCI-AD;
Albert et al., 2011) and the diagnosis of dementia due to AD (AD
dementia; McKhann et al., 2011), which also integrated biomarker
information. According to the NIA-AA workgroup, the major AD
biomarkers can be divided into those related to the process of brain
Aβ protein deposition, comprising low cerebrospinal ﬂuid (CSF)
Aβ42 and positive positron emission tomography (PET) amyloid
imaging, and those related to downstream neuronal degeneration
or injury: elevated CSF tau, both total tau (t-tau) and phos-
phorylated tau (p-tau); decreased 18ﬂuorodeoxyglucose (FDG)
uptake on PET in the temporo–parietal cortex; and dispropor-
tionate atrophy on structural magnetic resonance imaging (MRI)
in medial, basal and lateral temporal lobe, and medial parietal
cortex; McKhann et al., 2011).
According to the NIA-AA recommendations (Albert et al.,
2011), in the presence of a change in cognition, objective impair-
ment in at least one cognitive domain, preservation of inde-
pendence in ADL (and inherent absence of dementia), clinical
syndrome suggestive of AD and examination of potential causes
consistent with AD, an individual is classiﬁed as having MCI-AD-
core clinical criteria in the following situations: (1) in the absence
of information on biomarkers; (2) in the event that they are unin-
formative (neither clearly negative nor positive); or (3) in the case
that their information is conﬂicting (e.g., low Aβ and normal tau
in CSF). The “suggestive” clinical syndrome involves typically a
prominent impairment in episodic memory, but other patterns,
such as visuo-spatial impairment, are also possible manifestations
of underlying AD pathology and, as such, are compatible with a
diagnosis of MCI-AD. A subject is attributed a diagnosis of MCI-
AD with intermediate likelihood if he has one positive biomarker
either reﬂectingAβdepositionor neuronal injury.Aperson is diag-
nosed with MCI-AD with a high likelihood if both biomarkers are
positive. An individual is attributed a diagnosis of MCI unlikely
due to AD if both biomarkers are negative.
Regarding AD dementia, the NIA-AA workgroup (McKhann
et al., 2011) proposes the following terminology: (1) probable AD
dementia, (2) possible AD dementia, (3) probable or possible AD
dementia with evidence of the AD pathophysiological process.
The ﬁrst two concepts are intended for use in all clinical settings.
The third is to be used for research purposes only. The authors
underline that dementia from all causes implies the presence of
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cognitive decline from previous levels of performance, detected by
history taking and objective assessment, involving a minimum of
two domains, interfering with ADL and not explained by delirium
ormajor psychiatric disorder. According toMcKhann et al. (2011),
probable AD dementia is diagnosed when the patient meets cri-
teria for dementia and, in addition, there is clear-cut history of
worsening of cognition by report or observation, insidious onset,
and the initial and most prominent cognitive deﬁcits are in one
of the following categories: memory, language, visuo-spatial func-
tion, or executive function. The NIA-AA workgroup recommends
that the diagnosis of probable AD dementia should not be applied
when there is evidence of substantial concomitant cerebrovascular
disease, core features of Dementia with Lewy bodies (DLB; other
thandementia itself),prominent features of fronto-temporal lobar
degeneration (FTLD), evidence of another concurrent, active neu-
rological disease, or of a non-neurological medical comorbidity or
use of medication that could have a substantial effect on cogni-
tion. In persons who meet the core clinical criteria for probable
AD dementia, the authors (McKhann et al., 2011) postulate an
increased level of certainty of diagnosis in the presence of: docu-
mented decline and/or causative AD genetic mutation. According
to the same workgroup, a diagnosis of possible AD dementia is
made when there is an atypical course, that is, when there is sud-
den onset of cognitive impairment, or insufﬁcient historical detail
or objective cognitive documentation of progressive decline, or
when there is an etiologically mixed presentation.
McKhann et al. (2011) state that, in persons who meet the core
clinical criteria for probable AD dementia, biomarker evidence
may increase the certainty that the basis of the clinical demen-
tia syndrome is the AD pathophysiological process. However, the
authors do not advocate the use of AD biomarker tests for routine
diagnostic purposes at the present time. They indicate the reasons
for this limitation: the very good diagnostic accuracy of the core
clinical criteria; the need for more research validating the design of
the biomarker incorporating criteria; the limited standardization
of biomarkers from one site to another; and the limited access to
biomarkers in many community settings.
AD VARIANTS
Typically, AD presents with initial episodic memory dysfunction,
followed by progressive involvement of other cognitive domains,
including praxis, visuo-spatial orientation, language, calculation
and executive functions. Deﬁcit progression mirrors the suc-
cessive involvement of different brain regions, beginning with
hippocampal damage and spreading to lateral temporal regions,
parieto-occipital cortex and frontal lobe structures. However, AD
pathology is also found in patients presenting with different clini-
cal symptoms, caused by initial damage on less frequently involved
cortical regions. These atypical cases pose diagnostic difﬁculties,
and are frequently identiﬁed as non-AD cases, including FTLD,
Lewy-body disease (LBD) and cortico-basal degeneration (CBD),
in which non-memory deﬁcits are more frequent. Atypical AD
patients present in at least two different patterns. The syndrome of
posterior cortical atrophy (PCA) involves dysfunctionof the visuo-
spatial areas of the occipital and parietal cortices. Primary pro-
gressive aphasia (PPA) affects almost exclusively language related
structures.
The PCA syndrome, ﬁrst described by Benson et al. (1988),
is characterized by the early appearance (before the age of 60)
of alexia with agraphia (the most frequent symptoms, which
occur without signiﬁcant derangement of other language related
functions), Balint’s syndrome (optic ataxia, ocular apraxia, simul-
tanagnosia, and visual agnosia) and Gerstmann syndrome, with
acalculia as the predominant symptom (Galton et al., 2000; Tang-
Wai et al., 2004; McMonagle et al., 2006; Alladi et al., 2007). Some
cases present with predominant parietal dysfunction (involving
the dorsal stream of visual perception – the where stream), mani-
fested by agraphia and apraxia, and others show occipital dysfunc-
tion (involving the ventral stream – the what stream), expressed
by symptoms of visual agnosia, prosopagnosia, achromatopsia
and alexia. A third PCA group has been suggested, consisting of
patients with cortical blindness, caused by degeneration of the
occipital primary visual cortex (Galton et al., 2000). MRI stud-
ies have shown atrophy in regions related to the cognitive deﬁcits
found on neuropsychological evaluation, and relative preservation
of temporal mesial regions. However, not all cases show conspic-
uous atrophy on MRI. Functional imaging shows hypofunction
of the regions responsible for the cognitive deﬁcits. Many cases
evolve to full-blown dementia, including affection of episodic
memory and other cognitive domains.Nevertheless, some patients
maintain exclusive derangement of posterior cortical functions
for many years, and some die without presenting the complete
late stage AD pattern (Galton et al., 2000; Alladi et al., 2007).
Although PCA is deﬁned as a syndrome, caused by different dis-
eases that affect the posterior cortex (including LBD,priondiseases
and CBD), neuropathological examination shows a marked pre-
dominance of AD cases (Renner et al., 2004). Renner et al. (2004)
were not able to ﬁnd clinical differences between AD and non-AD
PCA cases, although some LBD patients would eventually develop
the visual hallucinations and extra-pyramidal symptoms charac-
teristic of the disease (Tang-Wai et al., 2004; McMonagle et al.,
2006). AD parietal atrophy cases were also difﬁcult to differentiate
from CBD cases.
Primary progressive aphasia was ﬁrst described by Mesulam
as a syndrome consisting of progressive deterioration of lan-
guage and preservation of other cognitive functions, associated
with left temporal and frontal lobe atrophy (Mesulam, 2001). As
these cases were primarily associated with the FTLD spectrum
of diseases, the existence of early language deﬁcits was usually
considered as an exclusion criteria for AD. Further investigation
has revealed that AD could underlie a higher percentage of PPA
cases than was ﬁrst considered. The syndrome of primary apha-
sia was classically divided into two distinct patterns: non-ﬂuent
aphasia and semantic dementia. Recently, a third pattern was pro-
posed, consisting of patients who seem to share deﬁcits belonging
to the other categories: slow speech and word ﬁnding difﬁcul-
ties (as in non-ﬂuent aphasia), with preservation of grammar and
phonological functions and presence of deﬁcits in naming (sim-
ilar to semantic dementia). Difﬁculty in sentence repetition and
in understanding long sentences, with preserved ability to under-
stand single words are also characteristic. This particular kind of
PPA, named logopenic aphasia, has been linked by imaging and
functional studies to atrophy of the left temporo-parietal junction,
including the left posterior superior and middle temporal gyri
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and inferior parietal lobule (Henry and Gorno-Tempini, 2010).
AD pathology could be present in about 20–30% of patients with
PPA. Interestingly, it appears to be linked with particular types of
PPA. While atypical Alzheimer cases rarely present with semantic
and non-ﬂuent aphasia, AD pathology appears to be common
in logopenic patients, as proven by clinical-pathological studies
(Alladi et al., 2007; Mesulam et al., 2008) and by imaging studies
using Pittsburgh compound B (PiB; Rabinovici et al., 2008).
A frontal variant of AD has also been reported, characterized
by prominent executive and behavioral symptoms, mimicking the
behavioral variant of FTLD, but presenting with AD pathology
and selective deposition of amyloid in frontal regions (Johnson
et al., 1999; Alladi et al., 2007). These ﬁndings have not been repli-
cated in other studies, and the existence of this variant remains
controversial.
The prevalence of ADatypical variants is unknown. In the study
by Galton et al. (2000), atypical cases represented 14% of all AD
cases followed in the institution. This was, however, a tertiary cen-
ter of referral, in which atypical cases could be over-represented.
In the mentioned study, PCA was present in 6 out of 26 atypical
cases, while 20 had the aphasic variant (Galton et al., 2000). Lit-
tle is known about the relative predominance of AD pathology in
the total number of patients presenting with focal cortical symp-
toms, as compared to FTLD, DLB, and CBD pathology. In a study
performed in 100 patients with focal cortical syndromes, AD was
present in all PCA cases and inmore than half of themixed aphasic
cases (a groupwhich includedpatientswith the logopenic variant).
Half of the cortical basal syndrome (CBS) cases, about 40% of the
patients with the non-ﬂuent aphasia syndrome and a small per-
centage with behavioral FTLD and semantic dementia syndromes
had AD pathology (Alladi et al., 2007). This suggests that, while a
diagnosis of PCA represents a high probability of AD, symptoms
characteristic of FTLD (particularly the progressive non-ﬂuent
aphasia type) or CBS should not rule out this diagnosis.
FIRST APPROACH TO THE PATIENT
The European Federation of Neurological Societies (EFNS) guide-
lines for the diagnosis and management of AD (Hort et al., 2010)
recommend that the evaluation of a subject suspected of having
AD should include history, from the patient and a close infor-
mant, focused on the affected cognitive domains, the course of the
illness, the impact on the ADL and any associated non-cognitive
symptoms.
Global assessment of cognitive functions should be undertaken,
using, for example, Mini-Mental State Examination (MMSE; Fol-
stein et al., 1975). Such a screening test is useful for the identiﬁca-
tion of cases requiringmore detailed evaluation. This is done using
neuropsychological tests assessing memory, executive functions,
language, praxis and visuo-spatial abilities (Hort et al., 2010).
As the differentiation of dementia from MCI rests on the deter-
mination of whether or not there is signiﬁcant interference in the
ability to function at work or in usual daily activities, it is useful to
assess ADL. However, there is no gold standard available for this
purpose (Hort et al., 2010). In a review by Sikkes et al. (2009),
out of several systematically reviewed scales, the informant-based
questionnaires the Disability Assessment for Dementia and the
Bristol ADL were among the most useful. The AD8, a brief
informant-based questionnaire that is able to differentiate between
non-demented anddemented individuals in a trustworthymanner
(Galvin et al., 2005), is also helpful.
Behavioral and psychological symptoms, as well as co-morbid
conditions, should be identiﬁed, since they occur in the majority
of AD patients and are associated with decline in cognitive and
functional ability (Apostolova and Cummings, 2008), decreased
quality of life and increased institutionalization (Hort et al., 2010).
Hort et al. (2010) also consider important to elicit past med-
ical history, co-morbidities, family and educational history. It is
stressed that neurological and general physical examination are
helpful in distinguishingAD from other primary degenerative and
secondary dementias and co-morbidities.
Blood tests, according to theEFNSguidelines (Hort et al., 2010),
are useful in excluding co-morbidities and should include vitamin
B12, folate, thyroid stimulating hormone, calcium, glucose, com-
plete blood cell count, renal and liver function. Syphilis, Borrelia
and HIV serological tests should be considered in high risk cases
or when there are suggestive clinical features.
Structural brain imaging is useful in excluding potentially sur-
gically treatable diseases and in detecting speciﬁc ﬁndings for AD.
For the former, CT and MRI are similarly good and it is consen-
sual that such an imaging procedure should be carried out once in
every patient. However, MRI is more sensitive to subtle vascular
changes and to alterations speciﬁc of certain conditions. For prac-
tice purposes, a standard MRI protocol involving at least coronal
T1 and axial T2 or ﬂuid-attenuated inversion recovery sequences
should be used (Hort et al., 2010).
Electroencephalography (EEG) may help to differentiate
betweenAD, subjective complaints andpsychiatric diagnoses. EEG
can also be useful in the differential diagnosis of atypical clinical
presentations of AD. Even though reduced alpha power, increased
theta power and lower mean frequency are characteristic of AD
patients, EEG can be normal early in the course of the disease in
up to 14% of cases (Hort et al., 2010).
NEUROPSYCHOLOGICAL EVALUATION
Episodic memory should be assessed because it is the function
most commonly impaired early in AD as a result of dysfunction
of mesial temporal structures, which are responsible for consoli-
dation. Retrieval, which depends on frontal lobe and subcortical
structures, is less affected (Hort et al., 2010).
Impaired delayed recall is not, per se, evidence of an AD-related
memory disorder. Authentic deﬁcits in encoding and storage
processes (features typical of AD) must be differentiated from
non-AD deﬁcits that can also affect delayed recall, including atten-
tional difﬁculties, which may be present in depression, and inefﬁ-
cient retrieval strategies, associated with normal aging, FTLD, or
subcortical-frontal dementias (Dubois et al., 2007).
Dubois et al. (2007) proposed the use of a neuropsychological
tool – the Grober-Buschke (GB) paradigm (Grober et al., 1988) –
which, controlling for elaborative encoding at study and providing
a strong category cue at retrieval, should be able to compensate
for eventual encoding/retrieval deﬁcits and allow to identify the
memory impairment that is caused by reduced efﬁciency of con-
solidation of the memory trace (Carlesimo et al., 2011). Within
this neuropsychological test paradigm, measures of sensitivity to
semantic cueing can successfully differentiate patients with AD
from healthy controls (Dubois et al., 2007).
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Sarazin et al. (2007) found that the most sensitive and speciﬁc
test for diagnosis of prodromalADwas the Free andCued Selective
Recall Reminding Test (FCSRT; Grober and Buschke, 1987). Their
study showed that impairment of free recall, total recall, and index
of sensitivity of cueing can identify prodromal AD in patients with
MCI with high sensitivity (79.7%) and speciﬁcity (89.9%).
In a series of studies reviewed by Carlesimo et al. (2011), total
immediate recall scores on the original or modiﬁed version of the
GB paradigm achieved levels of sensitivity between 62 and 100%
and of speciﬁcity between 93.9 and 100% in the discrimination
between AD and healthy elderly individuals. However, none of
these studies veriﬁed the diagnosis of AD using a postmortem
histologic examination.
On the other hand, the review by Carlesimo et al. (2011)
did not completely corroborate the superiority of the GB para-
digm over more traditional neuropsychological tools for analyzing
memory disorders in patients suspected of having AD. In fact,
controversial results emerged from studies that compared the sen-
sitivity/speciﬁcity of the cued recall task in the GB paradigm with
the free recall task in the same or a different experimental para-
digm in differentiating patients with full-blown AD or amnestic
MCI fromhealthy individuals. The authors (Carlesimo et al., 2011)
concluded that the GB procedure was useful for discriminating
whether an isolated memory deﬁcit in an elderly person is due to
incipient AD or to other causes and for helping in the differential
diagnosis between AD and other etiological forms of dementia.
In an interesting study involving 150 patients with an objective
history of episodicmemorydysfunction (Oksengard et al.,2010), it
was found that delayed recall, objectively assessed by Rey Auditory
Verbal Learning Test (RAVLT; Rey, 1958), was the most sensitive
marker in the detection of AD cases, when compared with MRI,
single photon emission tomography (SPECT), CSF t-tau, Aβ42,
and p-tau.
BIOMARKERS
MAGNETIC RESONANCE IMAGING
Atrophy of the medial temporal lobe atrophy (MTA) is a well-
recognized feature of AD, though there are limitations concerning
its speciﬁcity, because marked hippocampal atrophy has also been
shown in fronto-temporal dementia (Galton et al., 2001), demen-
tia with Lewy bodies (DLB; Barber et al., 2000), Parkinson’s disease
with dementia (Tam et al., 2005), vascular dementia (Barber et al.,
2000) and hippocampal sclerosis (Barkhof et al., 2007). However,
only one of these studies was in autopsy-conﬁrmed cases (Barkhof
et al., 2007) and thus misdiagnosis cannot be ruled out. Indeed, at
least two clinical-pathological studies showed high sensitivity and
speciﬁcity rates in the discrimination between AD and non-AD
dementias.
Burton et al. (2009) assessed the diagnostic speciﬁcity of
MTA, rated visually on MRI using a standardized scale (Schel-
tens et al., 1992), blind to clinical or autopsy diagnosis, for AD
among individuals with AD, DLB and vascular cognitive impair-
ment (VCI). The study group consisted of 46 individuals who had
both antemortem MRI and an autopsy. Subjects were patholog-
ically classiﬁed as AD, DLB, or VCI. MTA was a highly accurate
diagnostic marker for autopsy-conﬁrmed AD (sensitivity of 91%
and speciﬁcity of 94%).
Vemuri et al. (2011) created atrophy maps using structural
MRI and applied them for classiﬁcation of new incoming patients.
They identiﬁed 115 pathologically conﬁrmed subjects with a single
dementing pathologic diagnosis (AD,LBDor FTLD-TDP-43)who
had an MRI at the time of clinical diagnosis of dementia. Leave-
one-out classiﬁcation showed reasonable performance compared
to the autopsy “gold standard”: in AD, sensitivity was 90.7% and
speciﬁcity 84%.
A recent study (Karow et al., 2010) showed no evidence that
brain FDG PET was more sensitive than MRI to the degenera-
tion occurring in preclinical and mild AD. Thus, MRI, a practical
exam, might be used instead of more sophisticated ancillary tests
in clinical practice for early detection of AD.
New quantitative methods using MRI are promising biomark-
ers. These include: functional MRI and diffusion tensor imaging
(Hampel et al., 2008); diffusion weighted imaging, magnetiza-
tion transfer MRI and proton magnetic resonance spectroscopy
(Kantarci and Jack, 2003); and MR volumetry methods. The latter
encompass cortical thickness measurement, deformation-based
and voxel-based morphometry (Hampel et al., 2008), as well as
multiple-atlas propagation and segmentation technique (Leung
et al., 2010).
SINGLE PHOTON EMISSION TOMOGRAPHY
The EFNS guidelines (Hort et al., 2010) considered that SPECT
could increase diagnostic conﬁdence in the evaluation of demen-
tia. However, and even though it is more widely available and
cheaper than PET, it was not included in the Dubois criteria
(Dubois et al., 2007), because of its poor estimated diagnostic
accuracy. It is not mentioned in the recommendations from the
NIA-AA workgroup (McKhann et al., 2011), either.
Pooling data in an exploratory manner from two clinical-
pathological studies, Dougall et al. (2004) found a weighted
sensitivity for a “positive” brain SPECT (that is, one showing a
pattern of bilateral temporo-parietal hypoperfusion) of 74% and
a weighted speciﬁcity of 91% against neuropathology. In theses
studies using pathological veriﬁcation as a gold standard, clinical
criteria were more sensitive than brain SPECT (81 versus 74%)
and brain SPECT had a higher speciﬁcity than clinical criteria (91
versus 70%).
In the context of other clinical-pathological study, by Jagust
et al. (2001), the clinical diagnosis of probable AD was associated
with an 84% likelihood of pathologic AD. A positive perfusion
SPECT scan raised this likelihood to 92%, whereas a negative
SPECT scan lowered it to 70%. SPECT was more useful when
the clinical diagnosis was possible AD, with a likelihood of 67%
without SPECT, increasing to 84% with a positive SPECT, and
decreasing to 52% with a negative SPECT.
Dopaminergic SPECT imaging is useful to differentiate AD
from DLB with sensitivity and speciﬁcity around 85% (Hort et al.,
2010).
POSITRON EMISSION TOMOGRAPHY
FDG PET
In vivo brain FDG PET is a minimally invasive diagnostic
imaging procedure used to evaluate cerebral glucose metabolism.
The pattern of metabolic impairment of the posterior cingulate
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and temporo-parietal cortices, including the precuneus, more
accentuated than frontal cortex deﬁcits, together with relative
preservation of the primary sensorimotor and visual cortices,
basal ganglia, and cerebellum, constitutes the distinctivemetabolic
phenotype of AD (Bohnen et al., 2012).
Hoffman et al. (2000) studied FDG PET imaging in individ-
uals with difﬁcult-to-characterize memory loss or dementia who
eventually received pathologic conﬁrmation of diagnosis. The sen-
sitivity, speciﬁcity, and diagnostic accuracy of bilateral temporo-
parietal hypometabolism being associated with AD were 93, 63,
and 82%, respectively.
In a study by Silverman et al. (2001), using neuropathologi-
cal diagnosis as “gold standard,” PET was 94% sensitive and 73%
speciﬁc in identifying AD.
According to a study by Minoshima et al. (2001), PET could
distinguish autopsy-conﬁrmed AD and DLB patients with 90%
sensitivity and 80% speciﬁcity.
Another study, by Jagust et al. (2007), reported results of a
mixed sample of subjects with variable levels of cognitive impair-
ment, who eventually underwent autopsy. Results showed that
PET had sensitivity of 84% and speciﬁcity of 74% for the patho-
logic diagnosis of AD. The clinical diagnosis of AD was associated
with a 70% probability of detecting AD pathology; with a pos-
itive PET scan this increased to 84%, and with a negative PET
scan this decreased to 31%. A diagnosis of “not AD” at ini-
tial clinical evaluation was associated with a 35% probability
of AD pathology, increasing to 70% with a positive PET scan.
The probability of a postmortem diagnosis of AD for an ini-
tial normal cognitive assessment and negative FDG PET ﬁndings
was 17%.
In a study by Foster et al. (2007), involving patients with
pathologically conﬁrmed AD or FTLD, adding FDG PET to clin-
ical information increased the accuracy of AD diagnosis from 86
to 97%.
PiB PET
N -methyl-11C-2-(4-methylaminophenyl)-6-hydroxybenzothiazole,
also known as 11C-6-OH-BTA-1 or 11C-PiB, is an amyloid-
binding PET tracer.
The topological pattern of PiB binding in preclinical and clini-
cal AD patients comprises prefrontal cortex (PFC),medial parietal
cortex, lateral temporal cortex, striatum and posterior cingulate
cortex (PCC), with PFC being the region with earliest and most
pronounced uptake (Prvulovic and Hampel, 2011).
The diagnostic sensitivity of PiB to accurately classify AD
patients and control subjects is reported to average approximately
90% (Prvulovic and Hampel, 2011).
Devanand et al. (2010) evaluated 11C-PiB regional binding
potential (BPND, cerebellar reference) in individuals with clinical
diagnosis of mildAD,MCI and controls. Using a precuneus BPND
cut-point of 0.4087 (values above this considered abnormal), in
the differentiation of AD from controls, sensitivity was 0.944 and
speciﬁcity 0.944. In distinguishing MCI from controls, sensitivity
was 0.273 and speciﬁcity 0.944.
A puzzling fact is that 10–30% of asymptomatic healthy elderly
subjects have increased PiB uptake, a ﬁnding that is consistent with
several autopsy studieswhich foundAD-typical neuropathological
changes in a similar fraction of cognitively intact elderly indi-
viduals. On the other hand, a small fraction of AD patients do
not show any increase in PiB uptake, which may be explained
by inaccurate clinical diagnosis or the fact that PiB does not
bind to all ﬁbrillar Aβ conformations (Prvulovic and Hampel,
2011).
CSF ANALYSIS
The typical CSF pattern of AD consists of decreased levels of Aβ42
and increased values of t-tau or p-tau. Studies show that CSF Aβ42
changes before total tau (Isaac et al., 2011).
In a multicenter-study, CSF baseline concentrations of p-tau
predicted conversion to AD in subjects with MCI with high accu-
racy (80%)during an observation interval of 1.5 years (Ewers et al.,
2007; Prvulovic and Hampel, 2011).
A prospective cohort study (Visser et al., 2009) found that the
CSF AD proﬁle could identify patients with potential AD type
dementia among patients with MCI at sensitivities in the range of
88–91% and speciﬁcities between 52 and 90%.
In a large cross-sectional study involving patients with AD,
fronto-temporal dementia (FTD) and DLB, CSF concentrations
of p-tau-181 discriminated between DLB and AD with a sensi-
tivity of 94% and a speciﬁcity of 64%, while CSF concentrations
of p-tau-231 performed particularly well in the separation of AD
and FTD groups, with a sensitivity of 88% and a speciﬁcity of 92%
(Hampel et al., 2004).
Welge et al. (2009) found that combining CSF p-tau with
Aβ42/Aβ38 resulted in a sensitivity of 94% for detection of AD
and 85% speciﬁcity for excluding non-AD dementias.
In a clinical study by de Souza et al. (2011), the p-tau/Aβ42
ratio was the best biomarker for distinguishing AD from behav-
ioral variant FTLD and SD, with a sensitivity of 91.7 and 98.3%,
respectively, and a speciﬁcity of 92.6 and 84.2%, respectively.
Le Bastard et al. (2010) investigated the utility of CSF in cases
that had clinically ambiguous diagnoses, using autopsy-conﬁrmed
dementia diagnosis as gold standard. AD and non-AD patients
showed no signiﬁcant differences in CSF Aβ42 and t-tau con-
centrations, whereas p-tau (speciﬁcally p-tau-181) concentrations
were signiﬁcantly higher inAD compared to non-ADpatients. The
biomarker-based diagnostic model correctly classiﬁed 82% of the
patients.
Interestingly, in a study by Schoonenboom et al. (2012), CSF
AD biomarker proﬁle was seen in 47% of DLB cases, 38% of CBD
individuals, and in almost 30% of FTLD and vascular dementia
patients. Individuals with psychiatric diseases and with subjective
memory complaints had normal CSF biomarkers in 91 and 88%
of cases, respectively.
CANDIDATE BLOOD-BASED BIOMARKERS
There is evidence of peripheral oxidative damage correlating with
the occurrence of AD (Di Domenico et al., 2011). Thus, peripheral
oxidative biomarkers might be useful for early diagnosis and prog-
nosis. Complement factor H, alpha-2-macroglobulin, and clus-
terin have all been consistently associated with Alzheimer’s type
pathology (Ballard et al., 2011a). Ijsselstijn et al. (2011) identiﬁed
a signiﬁcant increase in concentration of pregnancy zone protein
(PZP) in pre-symptomatic AD, when compared with controls. At
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present, the use of plasma based Aβ cannot be recommended as
diagnostic biomarker for MCI and AD (Prvulovic and Hampel,
2011).
ROLE OF BIOMARKERS IN THE CLINICAL SETTING
It is currently difﬁcult to understand the relative importance of
different biomarkers when used together, and to interpret results
when biomarker data conﬂict with one another (Albert et al.,
2011).
Much work is still needed to determine the sensitivity, speci-
ﬁcity, and predictive value of biomarkers for a diagnosis of AD
in clinical samples. On the other hand, AD biomarkers allow
the detection of AD pathology in living individuals who have no
clinically discernible cognitive impairment. Such individuals are
considered to have preclinical AD, with the assumption that all
eventually will develop symptomatic AD if they live long enough
(Mayeux et al., 2011). However, it is known that some older indi-
vidualswith thepathophysiological process of ADmaynot become
symptomatic during their lifetime (Sperling et al., 2011). Use of
biomarkers in the clinical setting is thus currently unwarranted
because many individuals who satisfy the proposed research cri-
teria may not develop the clinical features of AD in their lifetime
(Sperling et al., 2011).
Nevertheless, biomarkers can be used as optional tools when
considered appropriate by the clinician (McKhann et al., 2011).
In our view, biomarkers should be used in MCI and demented
patients whose characteristics pose doubt as to etiology. The
choice of biomarkers depends on local availability and cost-
effectiveness issues, must take into consideration the time depen-
dence of biomarker changes during disease progression and the
main alternative differential diagnosis in the case in question.
PREDICTORS OF RATE OF DISEASE PROGRESSION
Factors that seem to increase the rate of disease progression (in
terms of cognitive and/or functional status) include: higher edu-
cation (Bruandet et al., 2008; Musicco et al., 2009, 2010; Roselli
et al., 2009); younger onset (Musicco et al., 2009; Tschanz et al.,
2011); increased baseline severity (Ito et al., 2011); psychosis (Stern
et al., 1994; Lopez et al., 1997); extrapyramidal signs (Mortimer
et al., 1992; Stern et al., 1994); lower CSF Aβ 42 levels, higher tau
or p-tau-181 levels, lower p-tau-181/tau ratio and higher tau/Aβ
42 ratios (Kester et al., 2009; Snider et al., 2009).
TREATMENT
The particular assembly of symptoms that each patient manifests
as a result of AD changes along the course of the disease and is
also different between patients. Added to the dynamic inﬂuence
of co-morbidities and co-medications, this fact may, at least par-
tially, explain why the effect of many treatments may vary both
intra and inter individually. Clinical trials, unable to control all
variables and limited by the complex task of detecting changes in
cognition or behavior, often reﬂect these heterogeneities by show-
ing a globally small, non-signiﬁcant or conﬂicting effect for the
treatment they are evaluating (Gauthier et al., 2010). Consider-
ing that many drugs (and other treatments) have signiﬁcant side
effects and costs, producing guidelines for the treatment of this
disease is not always clear-cut. Despite all this, good level of evi-
dence exists for some effects of a small group of drugs, and for
another group of treatments a more or less systematic effect can
also be expected, so that it is possible to advise on many aspects
of the management of this form of dementia with some degree
of certainty (Hort et al., 2010; Ballard et al., 2011a; Massoud and
Léger, 2011). Decisions at the level of a single patient, especially in
moderate and advanced disease, often have to be, though, based in
expert opinions, one’s previous experience or extrapolations from
other diseases.
The currently available treatments for AD are symptomatic.
They are able to, at least transiently, ameliorate some aspects of
cognition and function and reduce some neuropsychiatric symp-
toms, making patients and their entourage suffer less with the
disease. If patients under treatment see their therapies removed
after a certain time of continuous administration they will be
essentially indistinguishable from patients never treated, meaning
that this treatments are not intervening in disease progression.
The measures currently advocated to manage this form of
dementia involve adapting the patient’s environment and treating
the patient himself.
The interaction of a demented patient with the environment
around him is dysfunctional. Some measures can reduce the con-
sequences of this (Hort et al., 2010). The continuous education
of the caregivers, perhaps starting with setting real expectations as
to what to expect in terms of long-term evolution of symptoms
and treatment effect, is of primordial importance. The ability of
patients to correctly usemoney,medications, transports and home
appliances should be assessed and continuous adaptation of the
facilities at home and other pertinent environments should be
planned.Ability todrive should alsobe assessed according to global
(Iverson et al., 2010) and country-speciﬁc guidelines. Information
about social security, legal and other related matters should be sys-
tematized. The caregivers should be advised of the possibility of
their own exhaustion and strategies to avoid it should be foreseen.
Objectives of intervention in the patient himself can be concep-
tually divided in two: (transiently) revert some cognitive deﬁcits
and ameliorate functional capacity; and revert disturbing neu-
ropsychiatric symptoms or behaviors. These treatments may be
pharmacological or non-pharmacological.
The mainstay of treatment consists of a small group of drugs
that showed consistent, albeit small and variable, beneﬁts in well-
designed clinical trials. They are the only currently approved treat-
ments for AD by the authorities of most countries and include the
cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
and the NMDA receptor antagonist memantine (for a review of
the evidence see Herrmann et al., 2011). As stated above for the
treatment of AD in general, they show only a“symptomatic”effect,
although a neuroprotective potential has also been proposed.
Cholinesterase inhibitors are approved for mild to moderate
disease (usually MMSE between 16 and 26), where they proved
to have effect in cognition, global outcome and function when
compared to placebo (Birks and Harvey, 2006; Loy and Schneider,
2006; Birks et al., 2009). Weaker evidence shows some effect in
severe AD (Herrmann et al., 2011) and the FDA has also approved
donepezil for moderate to severe disease. These drugs show as
well beneﬁt in some neuropsychiatric symptoms, particularly apa-
thy, and somewhat less in psychosis. In clinical practice one can
generally expect to observe slight amelioration in cognition and
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stabilization in function,parameters which are presumed to return
to baseline or start degrading again after 6 to 12months of treat-
ment. Differences in drug metabolism may justify switching from
one cholinesterase inhibitor agent to another in cases of intoler-
ance or lack of effect (Massoud et al., 2011). The most common
side effects are gastrointestinal dysfunction, anorexia and sleep
disturbances. They can usually be avoided by titrating up the
dose. The most concerning side effects of these medications are
bradycardia and syncope, reasons for which it is advisable to eval-
uate preexisting bradycardia or cardiac conduction blocks with
an electrocardiogram and monitor blood pressure. Rivastigmine
administered in a transdermal patch has fewer side effects than its
oral form, maintaining the same beneﬁts (Winblad et al., 2007).
Memantine is approved for moderate to severe AD, where it
proved to have beneﬁcial effects in cognitive performance, func-
tion and global measures (McShane et al., 2006). Memantine
may also be useful in the prevention and treatment of agitation,
aggression, irritability and psychosis. As with cholinergic drugs,
one should expect stabilization of cognition and function for
6months after onset of treatment. Memantine is usually well tol-
erated. Dose-limiting side effects are rare and consist of dizziness,
headache, somnolence, and confusion.
There also seem to be additive beneﬁts of combining a
cholinesterase inhibitor and memantine (Tariot et al., 2004; Atri
et al., 2008; Lopez et al., 2009) albeit not all studies have supported
this (Porsteinsson et al., 2008).
The short duration of most trials with these four drugs pre-
cludes us from knowing the time for how long a difference from
placebo is maintained. The majority of experts advice caution in
stopping these drugs, although some reasons for discontinuation
may be advocated (Massoud et al., 2011).
Concerning non-pharmacological approaches to help main-
tain or enhance the cognitive, functional and global status of these
patients, current evidence suggests that cognitive training and cog-
nitive stimulation offer modest, albeit signiﬁcant, beneﬁts. The
results are mainly limited to the cognitive domains on which the
intervention is focused and, as these interventions are laborious,
cost-effectiveness studies are needed (Ballard et al., 2011b).
Another major topic in the treatment of AD is the approach
to certain frequent and disturbing neuropsychiatric symptoms
like apathy, depression, anxiety, psychosis, agitation, irritabil-
ity, aggression and sleep disturbances. There are no authority
approved treatments for these situations, which is a consequence
of lack of data, insufﬁcient or conﬂicting results and concerns
with possible side effects. In general terms, non-pharmacological
interventions are advocated ﬁrst (sleep hygiene measures, for
instance). When symptoms are very severe and menacing, phar-
macological treatment may be started immediately, accompanied
by non-pharmacological measures. Another general rule is that
drug treatments employed in this setting should be administered
in the minimal efﬁcacious dose and envisaged as transitory. Regis-
tering all the events prior to these manifestations helps to identify
possible environmental triggers.
For depression, when symptoms are mild and transient, non-
pharmacological approaches should be tried, like structured activ-
ities, such as day programs and daily exercise (Ballard et al., 2008).
Bright light therapy can aid sleep and reduce mood and behavioral
disturbance (Gauthier et al., 2010). For severe depression, most
clinicians use antidepressive drugs, whose efﬁcacy has been shown
in many trials, although not in all. Sertraline (100mg/day) is the
most documented drug, but other SSRI’s and other classes can be
tried, as long as side effects are considered (Gauthier et al., 2010;
Ballard et al., 2011a).
Neuroleptic drugs are commonly used to treat aggression, agi-
tation and psychosis. Efﬁcacy has been demonstrated for risperi-
done (especially 2mg/day) when prescribed for aggression, but
for agitation and psychosis, and for use of other neuroleptics,
results are weak or conﬂicting. Beneﬁts, which are often mod-
erate, must be weighed against potentially serious adverse events
like sedation, parkinsonism, chest infections, ankle edema, and
an increased risk of stroke and death. As already stated, mini-
mal effective doses should be used and long-term prescription
avoided. Anticonvulsants, like carbamazepine (useful for agita-
tion), and benzodiazepines may be helpful in selected cases. For
the ﬁrst one, potential drug interactions should not be forgotten,
and, for the latter, very short term use should be foreseen. Simple
non-pharmacological treatments, such as increasing physical and
social activity, aroma therapy (lavender and melissa), therapy with
animals, music therapy and simulated presence therapy (audio or
video tapes with familiars), can be effective alternatives (Ballard
et al., 2008, 2011a; Gauthier et al., 2010).
The treatment of AD also involves management of co-
morbidities. They often cause sudden aggravation of cognitive
deterioration or appearance of neuropsychiatric symptoms. In
these situations, so called “medical” causes, such as metabolic and
infectious diseases, as well as cerebrovascular pathologies,must be
actively sought and treated.
Other symptomswhichmust be dealt with (mostly in advanced
disease stages) include parkinsonism, gait instability, myoclonus,
seizures, contractures, pressure ulcers, pain, and undernutrition.
Concerning emerging treatment drugs, they are expected to
show less inter-individual variability and a more marked effect.
For that purpose, they must act directly in the mechanisms of
disease and be administered earlier in the course of AD, before sig-
niﬁcant neurodegeneration has occurred. Hopefully, biomarkers
will allow diagnosis before a dementia syndrome is installed and
permit testing drugs at a stagewhen they could be (more) effective.
Several lines of drug investigation are being pursued, some
targeting only symptomatic treatment, but the majority aiming
to show a disease-modifying effect (for reviews see Potter, 2010;
Herrmann et al., 2011; Salomone et al., 2012).
New cholinergic agents in investigation include direct and
allosteric muscarinic acetylcholine receptor agonists and also
agonists of certain subtypes of nicotinic receptors.
A group of drugs aiming to reduce Aβ production include:
rosiglitazone, which, among other modes of action, could inhibit
β secretase, was ineffective in a phase 3 trial, despite suggestion
of efﬁcacy in earlier data (Gold et al., 2010); semagacestat, a γ
secretase inhibitor, was tested in two phase 3 trials that had to
be prematurely stopped due to serious systemic adverse events
(Schor, 2011); several NSAID, including tarenﬂurbil, show a weak
modulating or inhibiting effect on γ secretase, but the tested ones
were not efﬁcacious in AD. Calcium channel blocker nilvadipine
could also reduce the production and augment the clearance of
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Aβ and is being clinically tested. Investigation of more potent and
speciﬁc inhibitors of γ secretase and efforts to produce α secretase
stimulating drugs are being undertaken. In the line of preventing
Aβ aggregation, tramiprosate, which, by binding toAβmonomers,
prevents formation of oligomers, did not show global clinical ben-
eﬁt in a phase 3 trial, although more studies are needed to clarify
its effects in some cognitive areas (Saumier et al., 2009). Other
drugs that could interfere in this stage of the Aβ cascade are the
zinc and copper chelators, curcumin (also proposed to have γ sec-
retase inhibiting properties), epigallocatechin-3-gallate (EGCG)
and scyllo-inositol, a compound that promotes dissociation of Aβ
oligomers.
Immunotherapy in AD is essentially being tried as a way of
clearing Aβ deposits through the use of antibodies against this
protein. Active immunization in the form of vaccines has pro-
duced severe adverse effects (meningoencephalitis), but different
techniques, inducing immunization against only a part of the Aβ
molecule and not all of it, are being thought of. Passive immu-
nization with monoclonal antibodies is at present under very
active clinical investigation. The most studied antibodies are bap-
ineuzumab, which is under various phase 3 trials with different
doses after a higher dose produced cerebral vasogenic edema in
almost 10% of the patients (Panza et al., 2011), and solanezumab,
also in phase 3 trials. Other strategies are being studied, including
the use of intravenous immunoglobulins (IVIG).
Lithium and valproate, besides other modes of action, could
reduce hyperphosphorylation of tau, but various clinical studies
have shown conﬂicting results. Other compounds judged to act in
tau phosphorylation and aggregation (including methylene blue)
are under investigation.
Other therapeutic strategies in development include the use
of nerve growth factor, etanercept and phosphodiesterase-5
inhibitors; interventions at the mitochondrial level (for instance
with latrepirdine and EGCG); inhibition of the receptor for
advanced glycation end products (RAGE); and the use of deep
brain stimulation (DBS). The roles of caffeine (or of whole cof-
fee) and of physical activity in the treatment of AD also deserve
clariﬁcation.
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